Status: withdrawn from the market

Organizations involved:

Lederle Labs. – Manuf.; R&D; Tech.; Former

Wyeth Pharmaceuticals – Parent co.; USA mark.; Former

Cross ref: See the Influenza Virus Vaccines entry (#470).

Cross ref: See the entries for Influenza Vaccine Products and the other influenza vaccine from Wyeth (#425).

Description: Flu-Immune was a conventional trivalent inactivated split (subvirion) influenza virus vaccine.

Nomenclature: Influenza Vaccine/Lederle [BIO]; Flu-Immune [TR]; Influenza Virus Vaccine [FDA USAN]; Influenza Virus Vaccine USP [USP]

Companies.: The vaccine was manufactured by Lederle Labs. (formerly subsidiary of American Cyanamid Co.; acquired by American Home Products Corp., now Wyeth), FDA CBER est. no. 0017. The 2001-2002 flu season was apparently the last Flu-Immune was manufactured/marketed. Flu-Immune was marketed by Wyeth in the U.S., and perhaps internationally

FDA class: Biologic PLA

CBER class: Viral And Rickettsial Vaccines

Indications: active immunization for prophylaxis against influenza virus infections

Status: Product license was recently voluntarily revoked (last reported as valid in 4/2004), and the product is no longer manufactured or marketed. In Nov. 2002, Wyeth announced halt of future manufacture of inactivated influenza vaccines to concentrate on marketing of FluMist, a live intranasal influenza vaccine (see #175), from MedImmune. Wyeth dropped marketing of FluMist after a disastrous product launch in the 2003-4 flu season.